“..WE ARE NOT POWERLESS, AND THROUGH OUR VIDEOS, WRITINGS, AND PHOTOGRAPHS, WE WILL EXPOSE THE ABUSES AND TYRANNY …JUST AS THE VIDEO WAS RECORDED BY THE CELL PHONE CAMERA OF YOUNG Darnella Frazier, BORE WITNESS TO THE MURDER OF GEORGE FLOYD, THE BLOG youarewithinthenorms.com bears WITNESS, AND BOTH ALLOWS THE SYSTEM TO BE HELD ACCOUNTABLE..”

“Timid women prefer the calm of Despotism to the tempestuous Sea of Liberty”

….norman j clement dds.

from youarewithinthenorms.com

NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH,  RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF FOREST TENNANT, MD., IN THE SPIRIT OF RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

Inside the Black Box: How PBMs Shape the Pharmacy Counter

introduction

The Evolution of the Gatekeeper: From Paper Shufflers to Power Players

In the original structure of American healthcare, Pharmacy Benefit Managers (PBMs) were designed as modest support beams. Thirty to forty years ago, they served as “pure” administrative processors—entities that managed paper claims and helped independent pharmacies operate more efficiently for a small administrative fee.

This article explores the predatory evolution of Pharmacy Benefit Managers (PBMs) and the Drug Enforcement Administration (D.E.A.), portraying them as invisible middleman conglomerates that have shifted from simple administrative tools to dominant gatekeepers of the American healthcare system. It also includes the Florida State Boards of Pharmacy, which have become ineffective, useless regulators, turning a blind eye to both PBM & D.E.A. abuses against independent pharmacies, adversely affecting the lives of patients and the licensure of pharmacists in Florida and beyond, thus failing their legal mandate under the State Statutes. The author argues that federal courts have wrongly permitted the DEA to ignore medical science and establish arbitrary “red flags” to prosecute healthcare providers without proof of criminal intent.

Using cases such as Pronto Pharmacy and citing the Supreme Court’s Ruan v. United States decision, the text asserts that the government lacks the medical expertise to dictate prescribing limits. Furthermore, documents a biased alliance between insurance companies and law enforcement that targets specific doctors using data analytics rather than clinical evidence. Most strikingly, the State Board of Pharmacy bodies have turned a blind eye to the constitutionality of seeking to overturn administrative tribunals in lieu of the recent United States Supreme Court determination of the illegality of the sanctions, (see JustCranky), maintaining that pharmacists and doctors are being unfairly treated as street drug dealers for providing essential pain management.

Drug formularies, patient data, and secret rebate “kickbacks,”… PBMs have evolved into a massive false healthcare reality of conglomerates that prioritize shareholder dividends over patient health outcomes,” and maximize profit margins at the expense of patients’ well-being. This article further highlights how PBMs employ vertical integration and “gag clauses” to reduce market transparency, often pushing consumers away from local pharmacies toward their own lucrative mail-order services. This narrative contends that this “unhealthy capitalism” creates a dangerous environment where artificially inflated costs and bureaucratic barriers can prevent access to life-saving medications.

Today, that “purity” has been replaced by a predatory infrastructure. PBMs have evolved into a massive, false healthcare reality of conglomerates that prioritize shareholder dividends over patient outcomes. They are no longer just service providers; they are the “paper shufflers who have everyone by the shorthairs.” In the industry, this transformation has earned them a new, darker nickname for the PBM acronym: “Drug-Piracy By Mail.”

This shift is driven by the market dominance of the “Big Three”:

• CVS Caremark (Owned by CVS Health)
• Express Scripts (Owned by Cigna)
• Optum RX (Owned by UnitedHealth)

Together, these three companies control approximately 80% of the market. Their scale is staggering: their parent companies are among the top 10 highest-revenue corporations in America, with UnitedHealth ranking #3 and CVS Health ranking #6.

This matters because these entities now exert total control over the flow of both money and medicine, sitting at the junction of manufacturers, insurers, and pharmacies as the “Invisible Gatekeepers.” While their corporate reach is vast, their power is maintained through a specific set of tools used to manage exactly what happens at the pharmacy counter.

——————————————————————————–

The Jargon of Control: Decoding PBM Tactics

To navigate the world of PBMs, one must understand the “Jargon of Control.” These are the mechanisms used to manage drug access, described by PBMs as clinical tools but functioning in reality as an aggressive profiteering engine.

The “Holy Grail” of this control is the Formulary—the list of drugs an insurance plan covers. PBMs use their access to millions of “lives” (insured members) to demand secret kickbacks, or rebates, for placement on this list.

Term	Official PBM Justification	The Real-World Barrier
Formulary Tiers	Sorting drugs by value to help patients choose cost-effective options.	Placement & Preference Power: PBMs move drugs to higher tiers to increase patient co-pays. If a manufacturer refuses to pay the rebate, the PBM “whacks” the drug, leaving it uncovered entirely.
Step Therapy	Ensuring patients try less expensive, effective treatments first.	Bureaucratic Block: A “fail first” policy that forces patients to suffer through a cheaper, often less effective drug before they can access the medication their doctor actually prescribed.
Prior Authorization	A clinical review to ensure a medication is necessary.	Access Barrier: Requires specific permission from the PBM bureaucracy, creating a “gatekeeper” delay that can prevent or stall life-saving treatment.
Specialty Drug Designation	A classification for complex or high-cost medications.	Patient Steering: This is a business term, not a clinical one. It is used to force patients away from their local community pharmacist and into PBM-owned mail-order facilities.

These tactical maneuvers are not random; they are driven by underlying economic incentives that fundamentally break the traditional rules of a marketplace.

——————————————————————————–

Unhealthy Capitalism: The Milk Test vs. The Black Box

In a healthy capitalist system, transparency drives competition and lowers costs. This is best illustrated by “The Milk Test.” If you want a gallon of milk and see it costs $2 at Target but $40 at Kroger, you exercise consumer choice and buy the cheaper option. In the PBM model, this logic is flipped upside down.

Feature	Normal Capitalism (The Milk Test)	The PBM Model (The “Black Box”)
Price Visibility	Consumers see the price tag clearly.	Prices are hidden; patients only see a PBM-mandated co-pay.
Consumer Choice	Shoppers switch stores for better deals.	Patients are forced into specific PBM-owned “channels.”
Market Incentives	Lower prices attract more customers.	Higher list prices are preferred to generate larger PBM rebates.
Data Access	Information is public and comparable.	Data is obscured behind “Gag Clauses” and “Black Boxes.”

A major tool in maintaining this “Black Box” is the Gag Clause. These are contractual rules that legally prevent your local pharmacist from telling you a secret: that the cash price for your medication might actually be cheaper than your insurance co-pay. By intentionally obscuring transparency, PBMs ensure that patients remain unaware of the true cost of their care.

This lack of transparency allows PBMs to profit from a counterintuitive reality: the more expensive a drug is, the more money the middleman makes.

——————————————————————————–

The Rebate Trap and the “Reverse Auction”

One might assume a “benefit manager” would want the lowest price for a drug. However, the PBM profit model incentivizes a “Reverse Auction” where high list prices are actually more lucrative for the PBM. This is the “smoking gun” of PBM logic: because their rebate is a percentage of the drug’s list price, they favor the most expensive medications.

The Logic of the Reverse Auction:

1. Higher List Price: A manufacturer sets a high price (e.g., $2,000).
2. Higher Rebate Percentage: The manufacturer offers a massive rebate (e.g., 50%) to the PBM for “preferred” placement on the formulary.
3. Higher PBM Profit: The PBM pockets a massive cut ($1,000) from the transaction.

PBMs frequently hide behind the phrase “Lowest Net Cost.” To a patient, this sounds like a saving. In PBM-speak, this is a myth. It refers to the cost that is lowest for the PBM after they pocket their cut. Because of this logic, a PBM will often exclude a “dirt-cheap generic” in favor of a $10,000-a-month brand-name drug simply because the kickback is higher.

——————————————————————————–

Vertical Integration: The Closed-Loop System

The “Big Three” have achieved vertical integration, meaning they own every link in the chain: the insurance company (the payer), the PBM (the middleman), and the pharmacy (the provider). This allows them to engage in “Patient Steering,” where they force or incentivize patients to use their own pharmacies.

The Three Dangers of Steering:

• Economic: PBMs often reimburse their own pharmacies 10 times more than they pay independent “mom-and-pop” pharmacies for the same drug. This causes “death by a thousand cuts” for local businesses, such as the 122-year-old pharmacy in Randolph, WI, which was recently forced to close its doors.
• Safety: PBMs steer patients toward mail-order facilities to maximize profit, but shipping can be hazardous. A study by Southwestern Oklahoma State University found that 100% of “cold-chain” drugs failed to maintain safe temperatures during shipping. Researchers recorded medications reaching a peak of 121°F in the back of delivery trucks.
• Choice: While PBMs claim patients have a choice, if a patient uses an independent pharmacy, their insurance benefits may not apply, leaving them with massive “out-of-network” costs.

While these systemic issues appear as numbers on a spreadsheet to a corporation, for patients, they can be a matter of life and death.

---

argument

“..The Erosion of the Rule of Law in Controlled Substance Oversight..”

The Rule of Law serves as the bedrock of the American legal system, a structural safeguard ensuring that government power is exercised only within the bounds of clear, statutory authority. When a federal agency begins to manufacture its own extra-legal standards and “own science” through administrative creep, it threatens the fundamental separation of powers between law enforcement and the practice of medicine.

In Series 9 YOUTUBE of Doctor Not Guilty, Dr. Muhamad Aly Rifai examines one of the most powerful figures in the federal criminal justice system: the prosecutor.

This systematic erosion is nowhere more apparent than in the recent conduct of the Drug Enforcement Administration (DEA), which has increasingly utilized mechanisms like Auer deference to circumvent legislative intent and seize property without adequate judicial oversight.

The thesis of this is clear: The DEA has transformed into a rogue sub-agency, operating as an unauthorized federal medical board in open defiance of the Controlled Substances Act (SCA). By ignoring the specific jurisdictional boundaries established by Congress, the DEA has moved beyond its role as a regulator of drug flow to become an arbiter of clinical practice.

This document outlines the legal and statutory framework that renders the DEA’s current enforcement tactics—specifically its use of algorithmic persecution and subjective standards—a violation of federal law. The transition from philosophical overreach to specific illegality begins with the statutory limitations Congress explicitly placed upon the Attorney General’s authority.

2. Statutory Authority and the Mandatory Role of Health Agencies

The legislative intent behind the Controlled Substances Act (CSA) is predicated on a single, vital distinction: medical expertise, not law enforcement intuition, must serve as the gatekeeper of drug scheduling and medical legitimacy. Congress recognized that federal agents are inherently “unqualified” to evaluate the clinical complexities of patient care. Consequently, the CSA establishes a closed regulatory system where law enforcement’s authority is strictly subordinate to the scientific and medical evaluations of specialized health agencies.

Under 21 U.S.C. § 811(b), the Attorney General is legally required to request a “scientific and medical evaluation” from the Secretary of Health and Human Services (HHS) before initiating drug scheduling. The statute is unambiguous: the Secretary’s recommendations are binding on the Attorney General regarding scientific and medical matters. This requirement ensures that law enforcement cannot unilaterally declare a substance’s medical utility—or lack thereof—based on enforcement priorities. Furthermore, 21 U.S.C. § 801(1)reinforces that law enforcement agencies lack the standing to determine whether a drug has a “useful and legitimate medical purpose” or is “necessary to maintain the health and general welfare of the American people.”

——————————————————————————–

Summary: The Learner’s Cheat Sheet

1. High Prices = High Profits: PBMs make more money when drug list prices stay high. They will actively block cheap generics to protect their high-percentage kickbacks.
2. The “Net Cost” Myth: “Lowest Net Cost” refers to the savings for the PBM, not the patient. These savings stay in the PBM’s bank account rather than lowering your price at the counter.
3. Vertical Monopolies: The “Big Three” control the insurer, the drug list, and the pharmacy, creating a closed loop that eliminates competition and strips patients of choice.

The current system is “upside down,” in which the entities meant to manage benefits have become the primary drivers of costs. As many in the industry have noted, “If criminals understood what PBMs were, it’s what they would aspire to be.” High-impact reform of this system is no longer just a policy preference—it is a matter of life and death.

THE MAN WHO WOULD NOT LOOK AWAY

Dr. Tennant’s life represented a tireless battle to give scientific visibility to invisible physical suffering, leaving behind a blueprint for compassionate, specialized neurological care.

“drug dealers in white coats” for what may actually be good-faith medical disagreements or errors..”

…from Ruan vs. United States Case 21-1014

🔓 🔓 🔓 

ALL WATCHED OVER BY MACHINES OF LOVING GRACE

ALL WATCHED OVER BY MACHINES OF LOVING GRACE

BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!

FOR NOW, YOU ARE WITHIN

THE NORMs

REFERENCES: